Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
129.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership
February 01, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
January 18, 2022
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 14, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Expert Ratings For Sarepta Therapeutics
December 09, 2021
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th...
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
November 04, 2021
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...
Via
Benzinga
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate
January 13, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on...
Via
Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
January 05, 2022
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
Upgrades For IGM Biosciences Inc (NASDAQ:
Via
Benzinga
Expert Ratings For Sarepta Therapeutics
October 15, 2021
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
November 04, 2021
The biotech stock fell a little more than $72 since its close last Friday.
Via
The Motley Fool
Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript
November 04, 2021
SRPT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Is This Beaten Down Biotech a Bad News Buy?
October 20, 2021
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
Via
The Motley Fool
Earnings Scheduled For November 3, 2021
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Why Sarepta Therapeutics Fell 14.7% This Week
October 14, 2021
Investors were unimpressed by the company's clinical and financial news.
Via
The Motley Fool
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
Why Sarepta Therapeutics Tumbled Today
October 13, 2021
Investors weren't wowed by a company update, or by news of a fresh stock issue.
Via
The Motley Fool
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes
October 13, 2021
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
5 Stocks To Watch For October 13, 2021
October 13, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Sarepta Therapeutics
October 12, 2021
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...
Via
Benzinga
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
October 11, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK...
Via
Benzinga
Sarepta, Codiak Nix Exosome Therapy Development Pact
October 08, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option...
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.